MedTrace Logo

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

NCT01498874 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2014-03-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether gevokizumab is effective in the treatment of moderate to severe acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Placebo

Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56

DRUG

gevokizumab

Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56

DRUG

gevokizumab

Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56

Sponsors & Collaborators

  • XOMA (US) LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-04-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01498874 on ClinicalTrials.gov